Roche POINT-HD
Great news for the HD community towards the end of 2025 This week Roche announced that recruitment has started for a new trial called POINT-HD. 40 participants will be included […]
New research grant to improve mental health support for people affected by Huntington’s disease
New research grant to improve mental health support for people affected by Huntington’s disease Huntington’s disease can have significant impacts on mental wellbeing for everybody in affected families. While the […]
The Impact of Economic Evaluations in HTAs: Why Access to Therapies May Vary Across Countries
The Impact of Economic Evaluations in HTAs: Why Access to Therapies May Vary Across Countries In the first article of this section dedicated to Health Technology Assessments (HTAs), we examined […]
uniQure Provides Regulatory Update on AMT-130
The regulators in the US require more data from Uniqure to evaluate their AMT-130 therapy We would like to share an important update released today by uniQure regarding AMT-130 after […]
Beyond numbers: The Impact of Iceland’s HD Association
Community Spotlight: Iceland 🇮🇸 Beyond numbers: The Impact of Iceland’s HD Association Iceland is one of the smallest countries in Europe, which represents both a challenge and a catalyst to […]
EHA at the Orphan Drug Conference in Amsterdam
EHA at the Orphan Drug Conference in Amsterdam Together Towards Fair Access for Rare Disease Therapies President Astri Arnesen attended the Orphan Drug Conference in Amsterdam to discuss how the […]
SOM Biotech secures clear registrational path for SOM3355 in HD after FDA End‑of‑Phase 2 Meeting
SOM3355: An «old» drug showing positive effect on psychiatric and motor symptoms in HD patients SOMBiotech is a company based in Europe that tests drugs for new purposes, so-called re-purposing. […]
Bucharest 2025
EHA CONFERENCE IN BUCHAREST 2025 The 2025 EHA Conference, held in Bucharest, Romania, from September 25th to 28th, brought together the HD community under the inspiring theme “Shaping our future […]
Recent results for AMT-130: a step towards treatments that could slow Huntington’s disease
Recent results for AMT-130 A step towards treatments that could slow Huntington’s disease In September 24th, the company UniQure announced the results of its clinical trial after 36 months with […]
Encouraging Phase 1 Results for Skyhawk’s Huntington’s Disease Investigational Treatment
Encouraging Phase 1 Results for Skyhawk’s Huntington’s Disease Investigational Treatment Skyhawk Therapeutics has shared a press release with positive news about SKY-0515, the experimental drug they developed and are studying […]